John Damianos, M.D. on Twitter
@Khanna_S summarizing bezlotoxumab and #FMT pic.twitter.com/KwypHDwF1w— John Damianos, M.D. (@john_damianosMD) October 23, 2022
Finch Therapeutics Presents PRISM-EXT Biomarker Data at ACG 2022 and Proceeds with Patient Dosing in Phase 3 Trial of CP101 in Recurrent C. Difficile Infection — Finch Therapeutics
SOMERVILLE, Mass., Oct. 24, 2022 (GLOBE NEWSWIRE) -- Finch Therapeutics Group, Inc. (“Finch” or “Finch Therapeutics”) (Nasdaq: FNCH), a clinical-stage microbiome therapeutics company leveraging its Human-First Discovery ® platform to develop a novel class of orally administered biological drugs,
Finch Therapeutics Presents PRISM-EXT Biomarker Data at ACG 2022 and Proceeds with Patient Dosing in Phase 3 Trial of CP101 in Recurrent C. Difficile Infection
SOMERVILLE, Mass., Oct. 24, 2022 (GLOBE NEWSWIRE) -- Finch Therapeutics Group, Inc. (“Finch” or “Finch Therapeutics”) (Nasdaq: FNCH), a clinical-stage...
Seres Therapeutics Presents SER-109 ECOSPOR IV Study Data at IDWeek and American College of Gastroenterology (ACG) 2022 Annual Meetings - Yahoo Finance
CAMBRIDGE, Mass., October 23, 2022--Seres Therapeutics, Inc. (Nasdaq: MCRB), a leading microbiome therapeutics company, announces the presentation of safety and efficacy data from its open-label Phase 3 ECOSPOR IV extension study evaluating investigational oral microbiome therapeutic SER-109 for the prevention of rCDI at the IDWeek 2022 and American College of Gastroenterology (ACG) 2022 Annual Meetings. Among the ECOSPOR IV study participants, many of whom have multiple comorbidities, SER-109 w
Seres Therapeutics’ ECOSPOR III Study Data on SER-109 Published in Journal of the American Medical Association - Yahoo Finance
CAMBRIDGE, Mass., October 19, 2022--Seres Therapeutics, Inc. (Nasdaq: MCRB), a leading microbiome therapeutics company, today announced the publication of Phase 3 clinical data in the Journal of the American Medical Association (JAMA), highlighting that the clinical benefits of investigational therapeutic SER-109 for preventing recurrent C. difficile infection (rCDI) were apparent as early as two weeks post-treatment and sustained for at least 24 weeks.
Clostridium Difficile Infections Pipeline Drugs and Companies Insight Report (2022): Analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments - Digital Journal
Clostridium Difficile Infections pipeline constitutes 25+ key companies continuously working towards developing 25+ Clostridium Difficile Infections treatment therapies, analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments analyzes DelveInsight. Clostridium Difficile Infections Overview Clostridium Difficile Infections, also known as Clostridioides difficile or C. difficile is a type of bacteria that causes […]
Extended Follow-up of Microbiome Therapeutic SER-109 Through 24 Weeks for Recurrent Clostridioides difficile Infection in a Randomized Clinical Trial
Extended Follow-up of Microbiome Therapeutic SER-109 Through 24 Weeks for Recurrent Clostridioides difficile Infection in a Randomized Clinical Trial
Tomorrow at 8:40 AM ET, Acurx Pharmaceuticals' will present a poster on Ibezapolstat, the Company's investigative therapy designed to treat patients with #CDiff at @IDWeek2022. For details: https://t.co/khD0p15Pme #IDWeek2022
Tomorrow at 8:40 AM ET, Acurx Pharmaceuticals' will present a poster on Ibezapolstat, the Company's investigative therapy designed to treat patients with #CDiff at @IDWeek2022. For details: https://t.co/khD0p15Pme #IDWeek2022— Antimicrobials Working Group (@AWG_News) October 19, 2022
2022 microbiome market trends report microbiome therapeutics market has advanced to phase 3 with seres therapeutics ser 109 and rebiotix rbx 2660 for recurrent c
Investigational Biotherapeutic Effective Against C. difficile. Up to 24 Months
The investigational microbiota-based live biotherapeutic, which was endorsed by the FDA's Vaccines and Related Biological Products Advisory Committee at the end of ...
The clinical evidence for postbiotics as microbial therapeutics
An optimally operating microbiome supports protective, metabolic, and immune functions, but disruptions produce metabolites and toxins which can be involved in many conditions. Probiotics have the ...
Five Microbiome Companies Making Waves in 2022 - Inside Precision Medicine
Investigational Biotherapeutic Effective Against C. difficile Up to 24 Months
The investigational microbiota-based live biotherapeutic, which was endorsed by the FDA's Vaccines and Related Biological Products Advisory Committee at the end of ...
MTIG on Twitter
.@SeresTX's microbiome therapeutics represent an entirely new class of potential medicines with promise across a wide range of diseases including #CDiff, ulcerative colitis, #AMR infections & GvHD and metastatic #melanoma. Read more: https://t.co/5eSOyNFkV1— MTIG (@MTIG_News) October 13, 2022
Summit Therapeutics to Present Ri-CoDIFy Trial Results for Microbiome-Sparing Ridinilazole at IDWeek 2022 - GlobeNewswire
Menlo Park, California, Oct. 13, 2022 (GLOBE NEWSWIRE) -- Summit Therapeutics Inc. (NASDAQ: SMMT) (“Summit,” “we,” or the “Company”) and its product...
SpectrumX Announces Lab Data Showing Its Spectricept™ Product Neutralises C. difficile Spores Within Minutes - Business Wire
FDA Committee Recommends Approval for Live Microbiota C Difficile Medication - MD Magazine
RBX2660 is a standardized, stabilized, investigational microbiota-based live biotherapeutic.
Investigational Biotherapeutic Effective Against C. difficile Up to 24 Months - Pharmacy Practice News
Seres Therapeutics to Present Clinical Results at IDWeek and American College of Gastroenterology (ACG) 2022 Annual Meeting | Seres Therapeutics
The Investor Relations website contains information about Seres Therapeutics's business for stockholders, potential investors, and financial analysts.
Ferring to Present Analyses for Investigational Microbiota-Based Live Biotherapeutic RBX2660 in Patients with Recurrent C. Difficile Infection at ACG 2022 - Business Wire
Investigational Biotherapeutic Effective Against C. difficile Up to 24 Months - Infectious Disease Special Edition
Acurx Pharmaceuticals Nears Enrollment Milestone; Ibezapolstat Continues To Score Impressive Data Treating C. Difficile Infections ($ACXP) - Marketscreener.com
Acurx Pharmaceuticals was getting bullish interest at over $4.00. Now at $3.40ish, the herd should be pouncing. The interest is in ACXP's ibezapolostat, a novel, orally administered antibiotic being... | October 11, 2022
Acurx Pharmaceuticals Nears Enrollment Milestone; Ibezapolstat Continues To Score Impressive Data Treating C. Difficile Infections ($ACXP) - Digital Journal
Acurx Pharmaceuticals was getting bullish interest at over $4.00. Now at $3.40ish, the herd should be pouncing. The interest is in ACXP’s ibezapolostat, a novel, orally administered antibiotic being developed as a Gram-Positive Selective Spectrum (GPSS™) antibacterial. While many potential new drugs show potential, this one can indeed be a game-changer in treating debilitating infections. […]
Clostridium Difficile Infections Pipeline Landscape Analysis of 25+ Companies by DelveInsight | Leading Players – Rebiotix, Seres Therapeutics, Acurx Pharmaceuticals, and Others - Digital Journal
DelveInsight’s, “Clostridium Difficile Infections Pipeline Insight, 2022” report provides comprehensive insights about 25+ companies and 25+ pipeline drugs in Clostridium Difficile Infections (Clostridium Difficile Associated Disease) pipeline landscape. Clostridium Difficile Infections Pipeline Insight, 2022″ report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the […]
FDA advisory committee votes for approval of first microbiome-based drug, despite data problems
Nature Reviews Drug Discovery - Discover the world’s best science and medicine | Nature.com
Investigational Biotherapeutic Effective Against C. difficile Up to 24 Months - Infectious Disease Special Edition
@EuropeVaccine #ClostridioidesDifficile #cdiff
#ClostridioidesDifficile #cdiff— Wiep Klaas Smits (@SmitsLab) October 7, 2022
RBX2660 for Treatment of Recurrent C. difficile Infection (rCDI) - Contagionlive.com
Drs Feuerstadt, Abraham, and Chopra discuss clinical trial data for RBX2660, a live biotherapeutic product, in treatment of recurrent C difficile infection (rCDI), as well as data with RBX2660 that were presented at DDW 2022.
Ferring to present analyses for investigational microbiota based live biotherapeutic rbx2660 in patients with recurrent c diff
RBX2660 for Treatment of Recurrent C. difficile Infection (rCDI) - MD Magazine
Drs Feuerstadt, Abraham, and Chopra discuss clinical trial data for RBX2660, a live biotherapeutic product, in treatment of recurrent C difficile infection (rCDI), as well as data with RBX2660 that were presented at DDW 2022.